Outcome of Board meeting held on 25.08.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Oxygenta Pharmaceutical's board, at its August 25, 2025 meeting, approved reclassifying four members of the Vankineni family (collectively holding about 2.55% or 9,42,700 equity shares) from 'Promoter Group' to 'Public' shareholders under SEBI Regulation 31A, pending stock exchange and shareholder approval. The outgoing MD/CFO Mr. Vankineni Sai Sudhakar and Independent Director Mr. Sanagari Kondal Reddy resigned effective August 18, 2025, citing a change in ownership and management (takeover). Board committees have been reconstituted with four new Additional Directors, and the AGM for FY 2024-25 is scheduled for September 19, 2025 via video conferencing.
This signals a takeover or change of control event at the company, with existing promoters exiting and new management taking over. Shareholders should expect changes in strategic direction under the new leadership, and the promoter group's reduced influence (reclassification of 2.55% stake to public) indicates a significant ownership transition.